 OCALA, Fla., Sept. 21, 2021 GLOBE NEWSWIRE -- AIM ImmunoTech Inc. NYSE American: AIM today announced positive progress with the companys meeting request to the U.S. Food and Drug Administration FDA concerning a Phase 2 clinical study of Ampligen as an infusion therapy for Post-COVID-19 Cognitive Dysfunction PCCD. The meeting request has been deemed sufficient for transfer to the FDAs Division of Neurology by the FDAs Covid Scientific Technical Triage Team. 